ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Mind-Blowing: Amgen's Aimovig Halves Length of Migraine Attacks in Phase III Study
.biospace
December 01, 2017Migraine sufferers may find some new relief as Amgen unveiled results from a late-stage study that shows its?Phase III drug Aimovig?reduced monthly migraine attacks in half. -
Ketamine may help treat migraine pain unresponsive to other therapies
europeanpharmaceuticalreview
October 24, 2017Ketamine, a medication commonly used for pain relief and increasingly used for depression, may help alleviate migraine pain… -
Cannabinoids suitable for migraine prevention
europeanpharmaceuticalreview
June 30, 2017A study has confirmed that cannabinoids are just as suitable as a prophylaxis for migraine attacks as other pharmaceutical treatments. -
Alder shares slump despite migraine success
pharmaphorum
June 29, 2017Alder BioPharmaceuticals announced that its migraine drug eptinezumab succeeded in a late-stage trial for migraine – but shares immediately fell as investors?raised concerns about a strong placebo effect. -
EU regulators review Novartis’ migraine drug
pharmatimes
June 23, 2017An experimental therapy being developed by Amgen and Novartis to prevent migraine has been accepted for review in the European Union. -
Novartis achieves regulatory milestone for AMG 334 in migraine prevention with EMA filing acceptance
cphi-online
June 23, 2017AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance. -
Panacea inks pact with UNICEF
financialexpress
January 20, 2017Gets US FDA nod for migraine drug
Pharma Sources Insight January 2025
